In this Q&A, Dr Machado answers our questions about the impact that biologic disease-modifying antirheumatic drugs have in axial spondyloarthritis remission.
Patients with pulmonary arterial hypertension may experience sleep disturbance and poor sleep quality. Lea Ann Matura, PhD, RN, answers our questions about the association between sleep and biomarkers among...
Joshua Z. Goldenberg, ND, answered our questions about his team’s study aimed to assess the efficacy and safety of biofeedback-based interventions for treating irritable bowel syndrome among adults and...
A study team recently examined the risk of ischemic strokes and transient ischemic attacks among patients who discontinued vitamin K antagonist therapy. We spoke with lead authors Carlos Martinez, MD, MSc,...
A new analysis of the ArthritisPower registry aimed to identify factors that patients believe influenced their physician’s treatment decisions. Lead authors W. Benjamin Nowell, PhD, and Kelly Gavigan, MPH,...
Atul Deodhar, MD, MRCP, from Oregon Health and Science University, answers our questions about the findings from the DISCOVER-1 clinical trial on the efficacy of guselkumab for the treatment of patients...
Diego J. Maselli, MD, answers our questions about choosing the right biologic for patients with severe asthma, the costs of biologics, and challenges to patient adherence to these therapies.
To determine the safety and impact of TLD on respiratory adverse events among patients with chronic obstructive pulmonary disease, a research team conducted a multicenter trial involving 82 patients....
W. Benjamin Nowell, PhD, answers our questions about his research on patient beliefs and perceptions relating to methotrexate use in the management of rheumatoid arthritis and psoriatic arthritis.
Sasha Bernatsky, MD, PhD, answers our questions about her research that evaluated treatment initiation and adjustments of methotrexate in early rheumatoid arthritis management.
